quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·28d
PRRelease
Medicus Pharma Ltd. logo

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

MDCX· Medicus Pharma Ltd.
Health Care
Original source

Companies

  • MDCX
    Medicus Pharma Ltd.
    Health Care

Related

  • SEC6h
    SEC Form 424B3 filed by Medicus Pharma Ltd.
  • SEC2d
    SEC Form PRE 14A filed by Medicus Pharma Ltd.
  • PR6d
    Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
  • PR8d
    Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
  • PR17d
    Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
  • INSIDER22d
    SEC Form 4 filed by Smith Andrew Alasdair
  • INSIDER22d
    SEC Form 4 filed by Rodgers Cathy Mcmorris
  • INSIDER22d
    SEC Form 4 filed by Raju Ajay
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022